See more : Paramount Group, Inc. (PGRE) Income Statement Analysis – Financial Results
Complete financial analysis of Athersys, Inc. (ATHX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Athersys, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Securitas AB (publ) (SCTBY) Income Statement Analysis – Financial Results
- Mechel PAO (MTL) Income Statement Analysis – Financial Results
- Finbar Group Limited (FRI.AX) Income Statement Analysis – Financial Results
- BH Macro Limited (BHMDF) Income Statement Analysis – Financial Results
- BrandShield Systems Plc (BRSD.L) Income Statement Analysis – Financial Results
Athersys, Inc. (ATHX)
About Athersys, Inc.
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.33M | 5.51M | 1.43M | 5.52M | 23.74M | 2.84M | 16.24M | 10.30M | 286.00K | 755.00K | 7.38M | 10.34M | 8.94M | 2.16M | 3.11M | 3.26M | 0.00 | 3.60M | 0.00 | 2.15M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | -554.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 5.33M | 5.51M | 1.43M | 5.52M | 24.29M | 2.84M | 16.24M | 11.95M | 1.62M | 2.44M | 8.71M | 10.34M | 8.94M | 2.16M | 3.11M | 3.26M | 0.00 | 3.60M | 0.00 | 2.15M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 102.33% | 100.00% | 100.00% | 116.02% | 567.48% | 322.91% | 117.99% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 100.00% |
| Research & Development | 65.03M | 71.08M | 62.99M | 39.05M | 38.66M | 27.84M | 24.84M | 21.32M | 23.37M | 20.48M | 19.64M | 18.93M | 14.78M | 11.92M | 16.50M | 15.82M | 0.00 | 12.58M | 0.00 | 13.68M |
| General & Administrative | 15.88M | 20.07M | 15.89M | 11.38M | 10.44M | 8.47M | 7.84M | 7.54M | 6.91M | 6.07M | 4.75M | 4.92M | 5.39M | 5.62M | 5.48M | 7.98M | 1.51K | 3.76M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.88M | 20.07M | 15.89M | 11.38M | 10.44M | 8.47M | 7.84M | 7.54M | 6.91M | 6.07M | 4.75M | 4.92M | 5.39M | 5.62M | 5.48M | 7.98M | 1.51K | 3.76M | 0.00 | 0.00 |
| Other Expenses | 1.42M | 1.43M | 882.00K | 582.00K | 762.00K | 314.00K | 209.00K | -61.00K | 86.00K | 38.00K | -1.17M | 278.00K | 284.00K | 233.00K | 218.00K | 283.00K | 0.00 | 982.00K | 0.00 | 22.19M |
| Operating Expenses | 82.33M | 92.57M | 79.76M | 51.01M | 49.40M | 36.13M | 31.95M | 27.47M | 29.30M | 25.21M | 23.38M | 24.12M | 20.45M | 17.77M | 22.20M | 24.08M | 1.51K | 17.32M | 0.00 | 35.86M |
| Cost & Expenses | 82.33M | 92.57M | 79.76M | 51.01M | 49.40M | 36.13M | 31.95M | 27.47M | 29.30M | 25.21M | 23.38M | 24.12M | 20.45M | 17.77M | 22.20M | 24.08M | 1.51K | 17.32M | 0.00 | 35.86M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 34.00K | 85.00K | 203.00K | 375.00K | 1.15M | 1.59M | 0.00 | 317.00K | 0.00 | 644.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 243.00K | 0.00 | 0.00 | 94.00K | 1.26M | 0.00 | 964.00K | 0.00 | 135.00K |
| Depreciation & Amortization | 1.42M | 1.43M | 890.00K | 698.00K | 855.00K | 684.00K | 382.00K | 267.00K | 360.00K | 346.00K | 320.00K | 278.00K | 284.00K | 233.00K | 218.00K | 231.00K | 0.00 | 938.00K | 0.00 | 1.80M |
| EBITDA | -75.59M | -85.63M | -77.44M | -44.79M | -25.42M | -33.33M | -15.03M | -17.17M | -29.01M | -24.46M | -16.00M | -20.82M | -11.23M | -15.62M | -18.91M | -20.82M | -1.51K | -12.50M | 0.00 | -30.83M |
| EBITDA Ratio | -1,419.51% | -1,552.97% | -5,407.96% | -811.85% | -107.11% | -1,172.25% | -95.15% | -171.64% | -12,322.73% | -2,355.89% | -245.05% | -130.04% | -124.82% | -706.62% | -609.44% | -677.70% | 0.00% | -347.72% | 0.00% | -1,432.57% |
| Operating Income | -77.01M | -87.06M | -78.33M | -45.49M | -25.05M | -33.28M | -15.03M | -17.17M | -29.01M | -24.46M | -16.00M | -13.78M | -11.51M | -15.62M | -19.09M | -20.82M | -1.51K | -13.97M | 0.00 | -34.78M |
| Operating Income Ratio | -1,446.18% | -1,578.85% | -5,470.11% | -824.51% | -105.51% | -1,170.70% | -92.54% | -166.74% | -10,144.06% | -3,239.34% | -216.82% | -133.22% | -128.77% | -723.25% | -614.88% | -638.50% | 0.00% | -388.49% | 0.00% | -1,616.36% |
| Total Other Income/Expenses | 4.48M | 103.00K | -433.00K | 906.00K | 762.00K | 1.04M | -348.00K | 711.00K | 6.68M | -6.29M | 1.27M | 34.00K | 134.00K | 249.00K | 1.10M | -3.57M | -52.00K | -233.00K | 0.00 | -1.08M |
| Income Before Tax | -72.53M | -86.96M | -78.77M | -44.58M | -24.28M | -32.24M | -15.37M | -16.46M | -22.34M | -30.74M | -14.74M | -24.39M | -11.38M | -17.99M | -17.99M | -24.39M | 0.00 | -14.20M | 0.00 | -35.86M |
| Income Before Tax Ratio | -1,362.14% | -1,576.99% | -5,500.35% | -808.08% | -102.30% | -1,134.05% | -94.68% | -159.84% | -7,809.44% | -4,071.92% | -199.66% | -235.74% | -127.27% | -833.35% | -579.45% | -748.01% | 0.00% | -394.97% | 0.00% | -1,666.36% |
| Income Tax Expense | -4.47M | 0.00 | 0.00 | 0.00 | 762.00K | -728.00K | -37.00K | -38.00K | -253.00K | 6.32M | -2.44M | -34.00K | -134.00K | -249.00K | -1.10M | -1.84M | 1.51K | 924.00K | 0.00 | -547.00K |
| Net Income | -68.06M | -86.96M | -78.77M | -44.58M | -24.28M | -32.24M | -15.34M | -16.42M | -22.08M | -30.74M | -14.74M | -13.75M | -11.38M | -15.37M | -17.99M | -18.93M | -1.51K | -14.60M | 0.00 | -33.16M |
| Net Income Ratio | -1,278.14% | -1,576.99% | -5,500.35% | -808.08% | -102.30% | -1,134.05% | -94.45% | -159.47% | -7,720.98% | -4,071.92% | -199.66% | -132.89% | -127.27% | -711.72% | -579.45% | -580.55% | 0.00% | -405.98% | 0.00% | -1,540.94% |
| EPS | -5.70 | -9.69 | -10.50 | -7.35 | -4.44 | -7.19 | -4.53 | -5.00 | -7.17 | -13.33 | -11.31 | -14.79 | -15.03 | -20.29 | -23.76 | -43.77 | -0.01 | -83.61 | 0.00 | -205.21 |
| EPS Diluted | -5.70 | -9.69 | -10.50 | -7.35 | -4.44 | -7.19 | -4.53 | -4.96 | -7.03 | -13.33 | -11.31 | -14.79 | -15.03 | -20.29 | -23.76 | -43.77 | -0.01 | -83.61 | 0.00 | -205.21 |
| Weighted Avg Shares Out | 11.95M | 8.97M | 7.50M | 6.07M | 5.47M | 4.48M | 3.39M | 3.29M | 3.08M | 2.31M | 1.30M | 929.56K | 757.19K | 757.14K | 757.12K | 432.45K | 175.53K | 174.62K | 179.28K | 161.59K |
| Weighted Avg Shares Out (Dil) | 11.95M | 8.97M | 7.50M | 6.07M | 5.47M | 4.48M | 3.39M | 3.31M | 3.14M | 2.31M | 1.30M | 929.56K | 757.19K | 757.14K | 757.12K | 432.45K | 175.53K | 174.62K | 179.28K | 161.59K |
Athersys, Inc. Announces Closing of $12 Million Registered Direct Offering
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) today announced the closing of its previously announced registered direct offering with a single healthcare-focused U.S. institutional investor for the purchase of 48,000,000 shares of the Company's common stock (or common stock equivalents in lieu...
Athersys, Inc. Announces $12 Million Registered Direct Offering
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) today announced that it has entered into a definitive agreement with a single healthcare-focused U.S. institutional investor for the purchase and sale of 48,000,000 shares of the Company's common stock (or common stock equivalents in...
Athersys, Inc. (ATHX) CEO Daniel Camardo on Q2 2022 Results - Earnings Call Transcript
Athersys, Inc. (NASDAQ:ATHX ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Cindy Jacobs - President, Chief Medical Officer & Director Jerry Wan - Principal Accounting Officer Daniel Camardo - Chief Executive Officer Conference Call...
Athersys Reports Second Quarter 2022 Financial Results and Provides Business Update
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and six months ended June 30, 2022 and provided a business update. Second quarter 2022 Corporate and Operational Highlights: Corporate Restructuring Implemented a restructuring of our organization...
Athersys Reports Second Quarter 2022 Financial Results and Provides Business Update
CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and six months ended June 30, 2022 and provided a business update. Second quarter 2022 Corporate and Operational Highlights: Corporate Restructuring Implemented a restructuring of...
Athersys Announces Favorable Preclinical Results for MultiStem® Treatment in Defense Department Radiation Countermeasure Study and Upcoming Webinar to Review Preclinical Research With MultiStem Across Multiple Indications
CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARS--Athersys, Inc. (Nasdaq: ATHX) announces today results of a radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRRI), a Department of Defense research laboratory under the leadership of the Uniformed Services University of the...
Athersys Appoints Kasey Rosado as Interim Chief Financial Officer
CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys Appoints Kasey Rosado as Interim Chief Financial Officer - Brings Operational Excellence and Financial Experience to Leadership Team
Best Penny Stocks To Buy As Recession Begins? 5 Biotech Stocks To Watch
Biotech penny stocks to watch this week. The post Best Penny Stocks To Buy As Recession Begins?
Athersys and Aspire Capital Fund Terminate Relationship
CLEVELAND--(BUSINESS WIRE)---- $ATHX--Athersys, Inc. (Nasdaq: ATHX) today announced that its equity purchase agreement with Aspire Capital Fund LLC (Aspire Capital) has been terminated. The Company continues to evaluate alternative financing options to support continuing operations. After several discussions with Aspire...
Athersys Announces Board of Directors Slate for 2022 Annual Meeting of Stockholders and Director Departures
CLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX--In connection with the Company's cost-cutting and restructuring initiatives, the Board of Directors approved reducing its size from 10 to 5 members.
Source: https://incomestatements.info
Category: Stock Reports